ClinicalTrials.gg
CompletedNCT04888507Updated Aug 29, 2025Results posted

Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy

A Phase 2 interventional study of Pozelimab and Cemdisiran in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Regeneron Pharmaceuticals. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-29.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals — 3 open to participants now, 3 under way, 2 of them phase 3. Hemoglobinuria, Paroxysmal · Regeneron Pharmaceuticals.

Started
2021
with 1 other
Phase 2
3 of 10
none open now
Registered
4th of 10
by date

Among the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals, this one is one of 2 that started in 2021, is one of 3 in phase 2, and was the 4th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

3 of the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the safety and tolerability of pozelimab and cemdisiran combination therapy in participants with PNH who switch from eculizumab therapy

The secondary objectives of the study are:

  • To evaluate the effect of the combination treatment on the following parameters of intravascular hemolysis: lactate dehydrogenase (LDH) control, breakthrough hemolysis, and inhibition of CH50
  • To evaluate the effect of the combination treatment on the stability of LDH during the transition period from eculizumab monotherapy to combination with pozelimab and cemdisiran
  • To evaluate the effect of the combination treatment on red blood cell (RBC) transfusion requirements
  • To evaluate the effect of the combination treatment on hemoglobin levels
  • To evaluate the effect of the combination treatment on clinical outcome assessments (COAs) measuring fatigue and health related quality of life (HRQoL)
  • To assess the concentrations of total pozelimab and eculizumab in serum; and total cemdisiran and C5 protein in plasma
  • To assess the immunogenicity of pozelimab and cemdisiran
  • To assess safety after dose intensification
  • To evaluate the long-term safety and efficacy of the combination treatment in an optional open-label extension period (OLEP)
03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria

Keywords

  • PNH
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Diagnosis of paroxysmal nocturnal hemoglobinuria confirmed by a history of high-sensitivity flow cytometry from prior testing
  2. Treated with stable (ie, no change in dose or frequency) eculizumab therapy at the labeled dosing regimen or a higher dose and/or more frequently administered than labeled for at least 12 weeks prior to screening visit

Key Exclusion Criteria:

  1. History of bone marrow transplantation or receipt of an organ transplant
  2. Body weight \<40 kg at screening
  3. Current plans for modification of the following background concomitant medications, as applicable, during screening and treatment period: erythropoietin, drugs, , anti-thrombotic agents, anticoagulants, iron supplements, and folic acid as described in the protocol
  4. Any use of complement inhibitor therapy other than eculizumab in the 12 weeks prior to the screening visit or planned use during the study
  5. Known hypocellular bone marrow based on a history of reduced age-adjusted bone marrow cellularity and/or bone marrow cellularity ≤25%
  6. No documented meningococcal vaccination within 5 years prior to screening visit unless it is documented that vaccination has been administered during the screening period and prior to initiation of study treatment
  7. Unable to take antibiotics for meningococcal prophylaxis, if required by local standard of care
  8. Any active, ongoing infection or a recent infection requiring ongoing systemic treatment with antibiotics, antivirals, or antifungals within 2 weeks of screening or during the screening period
  9. Documented positive polymerase chain reaction (PCR) or equivalent test based on regional recommendations for COVID-19 or suspected SARS-CoV-2 infection as described in the protocol
  10. Documented history of active, uncontrolled, ongoing systemic diseases
  11. Recent, unstable medical conditions, excluding PNH and PNH-related complications, within the past 3 months prior to screening visit as described in the protocol
  12. Anticipated need for major surgery during the study

NOTE: Other protocol-defined Inclusion/ Exclusion Criteria apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Pozelimab+Cemdisiran

    Drug: Pozelimab · Drug: Cemdisiran

Interventions

  • Intravenous (IV) loading dose (once) followed after 30 minutes by sub-cutaneous (SC) administration

    Also known as: REGN3918

  • SC administration

    Also known as: ALN-CC5

06

What researchers measure

Primary outcomes

  1. OLTP: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: Up to Day 225

Secondary outcomes

  1. OLTP: Percent Change in Lactate Dehydrogenase (LDH) From Pre-treatment to End-of-treatment Period

    Time frame: Screening (Day 1) through Day 225

  2. OLTP: Percent Change in LDH From Pre-treatment Through Day 29

    Time frame: Screening (Day 1) through Day 29

  3. OLTP: Percentage of Participants Who Were Transfusion-free From Baseline Through Week 32

    Time frame: Baseline through Week 32

  4. OLTP: Percentage of Participants Who Were Transfusion-free From Week 4 Through Week 32

    Time frame: Week 4 through Week 32

  5. OLTP: Rate of Red Blood Cell (RBC) Transfusions From Baseline Through Week 32

    The rate of units of transfusion for a participant was calculated based on the duration of treatment exposure of the participant.

    Time frame: Baseline through Week 32

  6. OLTP: Rate of RBC Transfusions From Week 4 Through Week 32

    The rate of units of transfusion for a participant was calculated based on the duration of treatment exposure of the participant.

    Time frame: Week 4 through Week 32

  7. OLTP: Number of RBC Units Transfused From Baseline Through Week 32

    Time frame: Baseline through Week 32

  8. OLTP: Number of RBC Units Transfused From Week 4 Through Week 32

    Time frame: Week 4 through Week 32

  9. OLTP: Percentage of Participants With Breakthrough Hemolysis From Baseline Through Week 32

    Breakthrough hemolysis was defined as having an LDH ≥ 2 x upper limit of normal (ULN) and having signs or symptoms.

    Time frame: Baseline through Week 32

  10. OLTP: Percentage of Participants With Breakthrough Hemolysis From Week 4 Through Week 32

    Breakthrough hemolysis was defined as having an LDH ≥ 2 x ULN and having signs or symptoms.

    Time frame: Week 4 through Week 32

  11. OLTP: Percentage of Participants Who Maintained Adequate Control of Hemolysis From Day 1 Through Week 32

    Adequate control was defined as LDH ≤ 1.5 x ULN from Day 1 through Week 32.

    Time frame: Day 1 through Week 32

  12. OLTP: Percentage of Participants Who Maintained Adequate Control of Hemolysis From Week 8 Through Week 32

    Adequate control was defined as LDH ≤ 1.5 x ULN from Week 8 through Week 32.

    Time frame: Week 8 through Week 32

  13. OLTP: Number of Participants With Adequate Control of Hemolysis at Each Visit

    Adequate control at a visit was defined as having LDH ≤1.5 x ULN at that visit.

    Time frame: Days 1, 8, 15, 29, 43, 57, 71, 85, 113, 141, 169, 197, 225

  14. OLTP: Number of Participants With Normalization of Their LDH at Each Visit

    Normalization was defined as LDH ≤ 1.0 x ULN at that visit.

    Time frame: Days 1, 8, 15, 29, 43, 57, 71, 85, 113, 141, 169, 197, 225

  15. OLTP: Average LDH From Baseline Through Week 32

    The trapezoidal rule was used to calculate area under the curve (AUC). Individual mean LDH is defined as AUC divided by (last assessment date of LDH - first assessment date of LDH) of specific period.

    Time frame: Baseline through Week 32

  16. OLTP: Average LDH From Week 8 Through Week 32

    The trapezoidal rule was used to calculate AUC. Individual mean LDH is defined as AUC divided by (last assessment date of LDH - first assessment date of LDH) of specific period.

    Time frame: Week 8 through Week 32

  17. OLTP: Percentage of Participants With Hemoglobin Stabilization From Baseline Through Week 32

    Hemoglobin stabilization was defined as not receiving an RBC transfusion and having no decrease in hemoglobin level of ≥ 2 grams per deciliter (g/dL).

    Time frame: Baseline through Week 32

  18. OLTP: Percentage of Participants With Hemoglobin Stabilization From Week 4 Through Week 32

    Hemoglobin stabilization was defined as not receiving an RBC transfusion and having no decrease in hemoglobin level of ≥ 2 g/dL.

    Time frame: Week 4 through Week 32

  19. OLTP: Change From Baseline in Hemoglobin Levels

    Time frame: Baseline, Week 32

  20. OLTP: Change From Baseline in Fatigue as Measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score

    The FACIT-Fatigue is a 13-item, self-reported measure assessing an individual's level of fatigue during their usual daily activities over the past week. This questionnaire is part of the FACIT measurement system, a compilation of questions measuring health-related quality of life (QoL) in participants with cancer and other chronic illnesses. The FACIT-fatigue assesses the level of fatigue using a Likert scale ranging from 0 (not at all) to 4 (very much). Total scores range from 0 to 52, with higher scores indicating a higher quality of life.

    Time frame: Baseline, Week 32

  21. OLTP: Change From Baseline in Health Related Quality of Life (HRQoL) as Measured by the Global Health Status Subscale of the European Organization for Research and Treatment of Cancer (EORTC)- Quality of Life Cancer Patients Questionnaire (QLQ) - 30 Scale

    EORTC-QLQ-C30 is a 30-item self-reported questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. The GHS subscale scores ranged from 0 to 100 with higher scores indicating better quality of life.

    Time frame: Baseline, Week 32

  22. OLTP: Change From Baseline in Physical Function (PF) Scores on the EORTC QLQ-C30

    EORTC-QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a PF scale. PF subscale scores ranged from 0 to 100 with higher scores indicating better quality of life.

    Time frame: Baseline, Week 32

  23. OLTP: Change From Baseline in Total Complement Hemolytic Activity Assay (CH50)

    This assay assessed the activity of the classical pathway of complement to measure C5 activity.

    Time frame: Baseline through Week 32

  24. OLTP and OLEP: Concentration of Total Pozelimab in Serum

    Time frame: Pre-dose Days 28, 56, 84, 112, 140, 168, 196, 224, 392, 588; Post-dose Day 28

  25. OLTP: Concentration of Total Eculizumab in Serum

    Time frame: Pre-dose Days 0, 14, 28, 56, 84, 112, 140, 168, 196, 224

  26. OLTP and OLEP: Concentration of Total Cemdisiran in Plasma

    Time frame: Pre-dose and Post-dose Days 0, 84, 196, 224, 588

  27. OLTP and OLEP: Concentration of Total C5 in Plasma

    Time frame: Pre-dose Days 0, 7, 14, 28, 56, 84, 112, 140, 168, 196, 224, 392, 588

  28. OLTP: Number of Participants With Pozelimab Anti-drug Antibodies (ADA)

    Time frame: Baseline through Week 32

  29. OLTP: Number of Participants With Cemdisiran ADA

    Time frame: Baseline through Week 32

  30. OLTP: Number of Participants Who Received Dose Intensification With TEAEs

    Time frame: Baseline through Week 32

  31. OLEP: Number of Participants With TEAEs

    Time frame: Day 1 through Week 52 of the OLEP

  32. OLEP: Percent Change in LDH From Day 1 Through Week 24 of the OLEP

    Time frame: Day 1 through Week 24 of the OLEP

  33. OLEP: Percent Change in LDH From Day 1 Through Week 52 of the OLEP

    Time frame: Day 1 through Week 52 of the OLEP

  34. OLEP: Percentage of Participants Who Were Transfusion-free From Day 1 Through Week 24 of the OLEP

    Time frame: Day 1 through Week 24 of the OLEP

  35. OLEP: Percentage of Participants Who Were Transfusion-free From Day 1 Through Week 52 of the OLEP

    Time frame: Day 1 through Week 52 of the OLEP

  36. OLEP: Rate of RBC Transfusions From Day 1 Through Week 24 of the OLEP

    The rate of units of transfusion for a participants was calculated based on the duration of treatment exposure of the participant.

    Time frame: Day 1 through Week 24 of the OLEP

  37. OLEP: Rate of RBC Transfusions From Day 1 Through Week 52 of the OLEP

    The rate of units of transfusion for a participants was calculated based on the duration of treatment exposure of the participant.

    Time frame: Day 1 through Week 52 of the OLEP

  38. OLEP: Number of RBC Units Transfused From Day 1 Through Week 24 of the OLEP

    Time frame: Day 1 through Week 24 of the OLEP

  39. OLEP: Number of RBC Units Transfused From Day 1 Through Week 52 of the OLEP

    Time frame: Day 1 through Week 52 of the OLEP

  40. OLEP: Percentage of Participants With Breakthrough Hemolysis From Day 1 Through Week 24 of the OLEP

    Breakthrough hemolysis was defined as having an LDH ≥ 2 x ULN and having signs or symptoms.

    Time frame: Day 1 through Week 24 of the OLEP

  41. OLEP: Percentage of Participants With Breakthrough Hemolysis From Day 1 Through Week 52 of the OLEP

    Breakthrough hemolysis was defined as having an LDH ≥ 2 x ULN and having signs or symptoms.

    Time frame: Day 1 through Week 52 of the OLEP

  42. OLEP: Percentage of Participants Who Maintained Adequate Control of Hemolysis From Day 1 Through Week 24 of the OLEP

    Adequate control was defined as LDH ≤ 1.5 x ULN.

    Time frame: Day 1 through Week 24 of the OLEP

  43. OLEP: Percentage of Participants Who Maintained Adequate Control of Hemolysis From Day 1 Through Week 52 of the OLEP

    Adequate control was defined as LDH ≤ 1.5 x ULN.

    Time frame: Day 1 through Week 52 of the OLEP

  44. OLEP: Number of Participants Who Maintained Adequate Control of Hemolysis at Each Visit in OLEP

    Adequate control was defined as LDH ≤ 1.5 x ULN at that visit.

    Time frame: Baseline, Days 57, 113, 169, 225, 281, 365 of the OLEP

  45. OLEP: Number of Participants With Normalization of Their LDH at Each Visit in OLEP

    Normalization was defined as LDH ≤ 1.0 x ULN at that visit.

    Time frame: Baseline, Days 57, 113, 169, 225, 281, 365 of the OLEP

  46. OLEP: Average LDH From Day 1 Through Week 24 of the OLEP

    The trapezoidal rule was used to calculate AUC. Individual mean LDH is defined as AUC divided by (last assessment date of LDH - first assessment date of LDH) of specific period.

    Time frame: Day 1 through Week 24 of the OLEP

  47. OLEP: Average LDH From Day 1 Through Week 52 of the OLEP

    The trapezoidal rule was used to calculate AUC. Individual mean LDH is defined as AUC divided by (last assessment date of LDH - first assessment date of LDH) of specific period.

    Time frame: Day 1 through Week 52 of the OLEP

  48. OLEP: Percentage of Participants With Hemoglobin Stabilization From Day 1 Through Week 24 of the OLEP

    Hemoglobin stabilization was defined as not receiving an RBC transfusion and having no decrease in hemoglobin level of ≥ 2 g/dL.

    Time frame: Day 1 through Week 24 of the OLEP

  49. OLEP: Percentage of Participants With Hemoglobin Stabilization From Day 1 Through Week 52 of the OLEP

    Hemoglobin stabilization was defined as not receiving an RBC transfusion and having no decrease in hemoglobin level of ≥ 2 g/dL.

    Time frame: Day 1 through Week 52 of the OLEP

  50. OLEP: Change From Baseline in Hemoglobin Levels

    Time frame: Day 1 and Week 24 of the OLEP

  51. OLEP: Change From Baseline in Hemoglobin Levels

    Time frame: Day 1 and Week 52 of the OLEP

  52. OLEP: Change From Baseline in FACIT-Fatigue Score

    The FACIT-Fatigue is a 13-item, self-reported measure assessing an individual's level of fatigue during their usual daily activities over the past week. This questionnaire is part of the FACIT measurement system, a compilation of questions measuring health-related quality of life (QoL) in patients with cancer and other chronic illnesses. The FACIT-fatigue assesses the level of fatigue using a Likert scale ranging from 0 (not at all) to 4 (very much). Total scores range from 0 to 52, with higher scores indicating a higher quality of life.

    Time frame: Day 1 and Week 52 of the OLEP

  53. OLEP: Change From Baseline in HRQoL as Measured by the Global Health Status Subscale of the EORTC-QLQ-30 Scale

    EORTC-QLQ-C30 is a 30-item self-reported questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. GHS subscale scores ranged from 0 to 100 with higher scores indicating better quality of life.

    Time frame: Day 1 and Week 52 of the OLEP

  54. OLEP: Change From Baseline in PF Scores on the EORTC QLQ-C30

    EORTC-QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a PF scale. PF subscale scores ranged from 0 to 100 with higher scores indicating better quality of life.

    Time frame: Day 1 and Week 52 of the OLEP

  55. OLEP: Change From Baseline in CH50

    This assay assessed the activity of the classical pathway of complement to measure C5 activity.

    Time frame: Baseline, Week 16, Week 32, Week 52 of the OLEP

  56. OLEP: Number of Participants With Pozelimab ADA

    Time frame: Day 1 through Week 52 of the OLEP

  57. OLEP: Number of Participants With Cemdisiran ADA

    Time frame: Day 1 through Week 52 of the OLEP

07

Results

Posted Jun 25, 2025

Participant flow

Open-Label Treatment (OLTP) (32 Weeks)
Participant flow — Open-Label Treatment (OLTP) (32 Weeks)
MilestoneParticipants With PNH
Started6
Completed5
Not completed1
Withdrew: Adverse event1
Open-Label Extension (OLEP) (52 Weeks)
Participant flow — Open-Label Extension (OLEP) (52 Weeks)
MilestoneParticipants With PNH
Started5
Completed5
Not completed0

Outcome measures

PrimaryOLTP: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time frame:
Up to Day 225
Reported as:
Count of participants · Participants
OLTP: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsParticipants With PNH
OLTP: Number of Participants With Treatment-emergent Adverse Events (TEAEs)6
SecondaryOLTP: Percent Change in Lactate Dehydrogenase (LDH) From Pre-treatment to End-of-treatment Period
Time frame:
Screening (Day 1) through Day 225
Reported as:
Mean · percent change
OLTP: Percent Change in Lactate Dehydrogenase (LDH) From Pre-treatment to End-of-treatment Period
percent changeParticipants With PNH
OLTP: Percent Change in Lactate Dehydrogenase (LDH) From Pre-treatment to End-of-treatment Period-0.95 ± 13.40
SecondaryOLTP: Percent Change in LDH From Pre-treatment Through Day 29
Time frame:
Screening (Day 1) through Day 29
Reported as:
Mean · percent change
OLTP: Percent Change in LDH From Pre-treatment Through Day 29
percent changeParticipants With PNH
OLTP: Percent Change in LDH From Pre-treatment Through Day 293.61 ± 35.99
SecondaryOLTP: Percentage of Participants Who Were Transfusion-free From Baseline Through Week 32
Time frame:
Baseline through Week 32
Reported as:
Number · percentage of participants
OLTP: Percentage of Participants Who Were Transfusion-free From Baseline Through Week 32
percentage of participantsParticipants With PNH
OLTP: Percentage of Participants Who Were Transfusion-free From Baseline Through Week 32100 (100.0 to 100.0)
SecondaryOLTP: Percentage of Participants Who Were Transfusion-free From Week 4 Through Week 32
Time frame:
Week 4 through Week 32
Reported as:
Number · percentage of participants
OLTP: Percentage of Participants Who Were Transfusion-free From Week 4 Through Week 32
percentage of participantsParticipants With PNH
OLTP: Percentage of Participants Who Were Transfusion-free From Week 4 Through Week 32100 (100.0 to 100.0)
SecondaryOLTP: Rate of Red Blood Cell (RBC) Transfusions From Baseline Through Week 32

The rate of units of transfusion for a participant was calculated based on the duration of treatment exposure of the participant.

Time frame:
Baseline through Week 32
Reported as:
Number · transfusions per person-year
OLTP: Rate of Red Blood Cell (RBC) Transfusions From Baseline Through Week 32
transfusions per person-yearParticipants With PNH
OLTP: Rate of Red Blood Cell (RBC) Transfusions From Baseline Through Week 320 (NA to NA)
SecondaryOLTP: Rate of RBC Transfusions From Week 4 Through Week 32

The rate of units of transfusion for a participant was calculated based on the duration of treatment exposure of the participant.

Time frame:
Week 4 through Week 32
Reported as:
Number · transfusions per person-year
OLTP: Rate of RBC Transfusions From Week 4 Through Week 32
transfusions per person-yearParticipants With PNH
OLTP: Rate of RBC Transfusions From Week 4 Through Week 320 (NA to NA)
SecondaryOLTP: Number of RBC Units Transfused From Baseline Through Week 32
Time frame:
Baseline through Week 32
Reported as:
Mean · RBC units
OLTP: Number of RBC Units Transfused From Baseline Through Week 32
RBC unitsParticipants With PNH
OLTP: Number of RBC Units Transfused From Baseline Through Week 320 ± 0.0
SecondaryOLTP: Number of RBC Units Transfused From Week 4 Through Week 32
Time frame:
Week 4 through Week 32
Reported as:
Mean · RBC units
OLTP: Number of RBC Units Transfused From Week 4 Through Week 32
RBC unitsParticipants With PNH
OLTP: Number of RBC Units Transfused From Week 4 Through Week 320 ± 0.0
SecondaryOLTP: Percentage of Participants With Breakthrough Hemolysis From Baseline Through Week 32

Breakthrough hemolysis was defined as having an LDH ≥ 2 x upper limit of normal (ULN) and having signs or symptoms.

Time frame:
Baseline through Week 32
Reported as:
Number · percentage of participants
OLTP: Percentage of Participants With Breakthrough Hemolysis From Baseline Through Week 32
percentage of participantsParticipants With PNH
OLTP: Percentage of Participants With Breakthrough Hemolysis From Baseline Through Week 320.0 (0.0 to 0.0)
SecondaryOLTP: Percentage of Participants With Breakthrough Hemolysis From Week 4 Through Week 32

Breakthrough hemolysis was defined as having an LDH ≥ 2 x ULN and having signs or symptoms.

Time frame:
Week 4 through Week 32
Reported as:
Number · percentage of participants
OLTP: Percentage of Participants With Breakthrough Hemolysis From Week 4 Through Week 32
percentage of participantsParticipants With PNH
OLTP: Percentage of Participants With Breakthrough Hemolysis From Week 4 Through Week 320.0 (0.0 to 0.0)
SecondaryOLTP: Percentage of Participants Who Maintained Adequate Control of Hemolysis From Day 1 Through Week 32

Adequate control was defined as LDH ≤ 1.5 x ULN from Day 1 through Week 32.

Time frame:
Day 1 through Week 32
Reported as:
Number · percentage of participants
OLTP: Percentage of Participants Who Maintained Adequate Control of Hemolysis From Day 1 Through Week 32
percentage of participantsParticipants With PNH
OLTP: Percentage of Participants Who Maintained Adequate Control of Hemolysis From Day 1 Through Week 3283.3 (53.5 to 100.0)
SecondaryOLTP: Percentage of Participants Who Maintained Adequate Control of Hemolysis From Week 8 Through Week 32

Adequate control was defined as LDH ≤ 1.5 x ULN from Week 8 through Week 32.

Time frame:
Week 8 through Week 32
Reported as:
Number · percentage of participants
OLTP: Percentage of Participants Who Maintained Adequate Control of Hemolysis From Week 8 Through Week 32
percentage of participantsParticipants With PNH
OLTP: Percentage of Participants Who Maintained Adequate Control of Hemolysis From Week 8 Through Week 3283.3 (53.5 to 100.0)
SecondaryOLTP: Number of Participants With Adequate Control of Hemolysis at Each Visit

Adequate control at a visit was defined as having LDH ≤1.5 x ULN at that visit.

Time frame:
Days 1, 8, 15, 29, 43, 57, 71, 85, 113, 141, 169, 197, 225
Reported as:
Count of participants · Participants
OLTP: Number of Participants With Adequate Control of Hemolysis at Each Visit
ParticipantsParticipants With PNH
Day 16
Day 85
Day 155
Day 296
Day 435
Day 575
Day 715
Day 855
Day 1134
Day 1415
Day 1694
Day 1973
Day 2255
SecondaryOLTP: Number of Participants With Normalization of Their LDH at Each Visit

Normalization was defined as LDH ≤ 1.0 x ULN at that visit.

Time frame:
Days 1, 8, 15, 29, 43, 57, 71, 85, 113, 141, 169, 197, 225
Reported as:
Count of participants · Participants
OLTP: Number of Participants With Normalization of Their LDH at Each Visit
ParticipantsParticipants With PNH
Day 16
Day 85
Day 155
Day 296
Day 435
Day 574
Day 715
Day 854
Day 1134
Day 1415
Day 1694
Day 1973
Day 2255
SecondaryOLTP: Average LDH From Baseline Through Week 32

The trapezoidal rule was used to calculate area under the curve (AUC). Individual mean LDH is defined as AUC divided by (last assessment date of LDH - first assessment date of LDH) of specific period.

Time frame:
Baseline through Week 32
Reported as:
Mean · Units per Liter (U/L)
OLTP: Average LDH From Baseline Through Week 32
Units per Liter (U/L)Participants With PNH
OLTP: Average LDH From Baseline Through Week 32227.34 ± 45.08
SecondaryOLTP: Average LDH From Week 8 Through Week 32

The trapezoidal rule was used to calculate AUC. Individual mean LDH is defined as AUC divided by (last assessment date of LDH - first assessment date of LDH) of specific period.

Time frame:
Week 8 through Week 32
Reported as:
Mean · U/L
OLTP: Average LDH From Week 8 Through Week 32
U/LParticipants With PNH
OLTP: Average LDH From Week 8 Through Week 32223.49 ± 49.01
SecondaryOLTP: Percentage of Participants With Hemoglobin Stabilization From Baseline Through Week 32

Hemoglobin stabilization was defined as not receiving an RBC transfusion and having no decrease in hemoglobin level of ≥ 2 grams per deciliter (g/dL).

Time frame:
Baseline through Week 32
Reported as:
Number · percentage of participants
OLTP: Percentage of Participants With Hemoglobin Stabilization From Baseline Through Week 32
percentage of participantsParticipants With PNH
OLTP: Percentage of Participants With Hemoglobin Stabilization From Baseline Through Week 32100 (100.0 to 100.0)
SecondaryOLTP: Percentage of Participants With Hemoglobin Stabilization From Week 4 Through Week 32

Hemoglobin stabilization was defined as not receiving an RBC transfusion and having no decrease in hemoglobin level of ≥ 2 g/dL.

Time frame:
Week 4 through Week 32
Reported as:
Number · percentage of participants
OLTP: Percentage of Participants With Hemoglobin Stabilization From Week 4 Through Week 32
percentage of participantsParticipants With PNH
OLTP: Percentage of Participants With Hemoglobin Stabilization From Week 4 Through Week 32100 (100.0 to 100.0)
SecondaryOLTP: Change From Baseline in Hemoglobin Levels
Time frame:
Baseline, Week 32
Reported as:
Mean · g/dL
OLTP: Change From Baseline in Hemoglobin Levels
g/dLParticipants With PNH
OLTP: Change From Baseline in Hemoglobin Levels0.54 ± 0.60
SecondaryOLTP: Change From Baseline in Fatigue as Measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score

The FACIT-Fatigue is a 13-item, self-reported measure assessing an individual's level of fatigue during their usual daily activities over the past week. This questionnaire is part of the FACIT measurement system, a compilation of questions measuring health-related quality of life (QoL) in participants with cancer and other chronic illnesses. The FACIT-fatigue assesses the level of fatigue using a Likert scale ranging from 0 (not at all) to 4 (very much). Total scores range from 0 to 52, with higher scores indicating a higher quality of life.

Time frame:
Baseline, Week 32
Reported as:
Mean · score on a scale
OLTP: Change From Baseline in Fatigue as Measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score
score on a scaleParticipants With PNH
OLTP: Change From Baseline in Fatigue as Measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score-1.0
SecondaryOLTP: Change From Baseline in Health Related Quality of Life (HRQoL) as Measured by the Global Health Status Subscale of the European Organization for Research and Treatment of Cancer (EORTC)- Quality of Life Cancer Patients Questionnaire (QLQ) - 30 Scale

EORTC-QLQ-C30 is a 30-item self-reported questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. The GHS subscale scores ranged from 0 to 100 with higher scores indicating better quality of life.

Time frame:
Baseline, Week 32
Reported as:
Mean · score on a scale
OLTP: Change From Baseline in Health Related Quality of Life (HRQoL) as Measured by the Global Health Status Subscale of the European Organization for Research and Treatment of Cancer (EORTC)- Quality of Life Cancer Patients Questionnaire (QLQ) - 30 Scale
score on a scaleParticipants With PNH
OLTP: Change From Baseline in Health Related Quality of Life (HRQoL) as Measured by the Global Health Status Subscale of the European Organization for Research and Treatment of Cancer (EORTC)- Quality of Life Cancer Patients Questionnaire (QLQ) - 30 Scale-8.333
SecondaryOLTP: Change From Baseline in Physical Function (PF) Scores on the EORTC QLQ-C30

EORTC-QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a PF scale. PF subscale scores ranged from 0 to 100 with higher scores indicating better quality of life.

Time frame:
Baseline, Week 32
Reported as:
Mean · score on a scale
OLTP: Change From Baseline in Physical Function (PF) Scores on the EORTC QLQ-C30
score on a scaleParticipants With PNH
OLTP: Change From Baseline in Physical Function (PF) Scores on the EORTC QLQ-C306.667
SecondaryOLTP: Change From Baseline in Total Complement Hemolytic Activity Assay (CH50)

This assay assessed the activity of the classical pathway of complement to measure C5 activity.

Time frame:
Baseline through Week 32
Reported as:
Mean · International units per mL (IU/mL)
OLTP: Change From Baseline in Total Complement Hemolytic Activity Assay (CH50)
International units per mL (IU/mL)Participants With PNH
OLTP: Change From Baseline in Total Complement Hemolytic Activity Assay (CH50)0.0 ± 0.0
SecondaryOLTP and OLEP: Concentration of Total Pozelimab in Serum
Time frame:
Pre-dose Days 28, 56, 84, 112, 140, 168, 196, 224, 392, 588; Post-dose Day 28
Reported as:
Mean · milligrams per liter (mg/L)
OLTP and OLEP: Concentration of Total Pozelimab in Serum
milligrams per liter (mg/L)Participants With PNH
Pre-dose Day 280 ± 0
15 Minutes Post-dose Day 281280 ± 193
Pre-dose Day 56333 ± 48.1
Pre-dose Day 84189 ± 54.8
Pre-dose Day 112121 ± 57.2
Pre-dose Day 140102 ± 40.7
Pre-dose Day 16870.1 ± 37.3
Pre-dose Day 19686.1 ± 36.6
Pre-dose Day 22471.7 ± 41.4
Pre-dose Day 39253.1 ± 25.6
Pre-dose Day 58851.1 ± 25.6
SecondaryOLTP: Concentration of Total Eculizumab in Serum
Time frame:
Pre-dose Days 0, 14, 28, 56, 84, 112, 140, 168, 196, 224
Reported as:
Mean · mg/L
OLTP: Concentration of Total Eculizumab in Serum
mg/LParticipants With PNH
Pre-dose Day 0231 ± 64.5
Pre-dose Day 14225 ± 63.2
Pre-dose Day 28242 ± 59.0
Pre-dose Day 56101 ± 42.9
Pre-dose Day 8444.4 ± 38.7
Pre-dose Day 11222.5 ± 29.5
Pre-dose Day 14012.6 ± 12.5
Pre-dose Day 1684.23 ± 6.46
Pre-dose Day 2240.540 ± 1.16
SecondaryOLTP and OLEP: Concentration of Total Cemdisiran in Plasma
Time frame:
Pre-dose and Post-dose Days 0, 84, 196, 224, 588
Reported as:
Mean · nanograms per milliliter (ng/mL)
OLTP and OLEP: Concentration of Total Cemdisiran in Plasma
nanograms per milliliter (ng/mL)Participants With PNH
Pre-dose Day 00 ± 0
Post-dose Day 0139 ± 45.5
Pre-dose Day 840 ± 0
Post-dose Day 84178 ± 111
Pre-dose Day 1960 ± 0
Post-dose Day 196196 ± 100
Pre-dose Day 2240 ± 0
Post-dose Day 224158 ± 75.7
Pre-dose Day 5880 ± 0
Post-dose Day 588215 ± 84.8
SecondaryOLTP and OLEP: Concentration of Total C5 in Plasma
Time frame:
Pre-dose Days 0, 7, 14, 28, 56, 84, 112, 140, 168, 196, 224, 392, 588
Reported as:
Mean · mg/L
OLTP and OLEP: Concentration of Total C5 in Plasma
mg/LParticipants With PNH
Pre-dose Day 0320 ± 64.2
Pre-Dose Day 7191 ± 46.2
Pre-dose Day 14118 ± 28.0
Pre-dose Day 2854.5 ± 14.2
Pre-dose Day 562.77 ± 6.78
Pre-dose Day 842.90 ± 6.48
Pre-dose Day 1123.88 ± 7.75
Pre-dose Day 1403.10 ± 6.93
Pre-dose Day 1684.79 ± 7.18
Pre-dose Day 1962.03 ± 4.05
Pre-dose Day 2244.96 ± 7.44
Pre-dose Day 3925.02 ± 7.13
Pre-dose Day 5885.28 ± 7.44
SecondaryOLTP: Number of Participants With Pozelimab Anti-drug Antibodies (ADA)
Time frame:
Baseline through Week 32
Reported as:
Count of participants · Participants
OLTP: Number of Participants With Pozelimab Anti-drug Antibodies (ADA)
ParticipantsParticipants With PNH
OLTP: Number of Participants With Pozelimab Anti-drug Antibodies (ADA)0
SecondaryOLTP: Number of Participants With Cemdisiran ADA
Time frame:
Baseline through Week 32
Reported as:
Count of participants · Participants
OLTP: Number of Participants With Cemdisiran ADA
ParticipantsParticipants With PNH
OLTP: Number of Participants With Cemdisiran ADA0
SecondaryOLTP: Number of Participants Who Received Dose Intensification With TEAEs
Time frame:
Baseline through Week 32

No measurements were reported for this outcome.

SecondaryOLEP: Number of Participants With TEAEs
Time frame:
Day 1 through Week 52 of the OLEP
Reported as:
Count of participants · Participants
OLEP: Number of Participants With TEAEs
ParticipantsParticipants With PNH
OLEP: Number of Participants With TEAEs5
SecondaryOLEP: Percent Change in LDH From Day 1 Through Week 24 of the OLEP
Time frame:
Day 1 through Week 24 of the OLEP
Reported as:
Mean · percent change
OLEP: Percent Change in LDH From Day 1 Through Week 24 of the OLEP
percent changeParticipants With PNH
OLEP: Percent Change in LDH From Day 1 Through Week 24 of the OLEP-6.17 ± 9.15
SecondaryOLEP: Percent Change in LDH From Day 1 Through Week 52 of the OLEP
Time frame:
Day 1 through Week 52 of the OLEP
Reported as:
Mean · percent change
OLEP: Percent Change in LDH From Day 1 Through Week 52 of the OLEP
percent changeParticipants With PNH
OLEP: Percent Change in LDH From Day 1 Through Week 52 of the OLEP-3.46 ± 10.94
SecondaryOLEP: Percentage of Participants Who Were Transfusion-free From Day 1 Through Week 24 of the OLEP
Time frame:
Day 1 through Week 24 of the OLEP
Reported as:
Number · percentage of participants
OLEP: Percentage of Participants Who Were Transfusion-free From Day 1 Through Week 24 of the OLEP
percentage of participantsParticipants With PNH
OLEP: Percentage of Participants Who Were Transfusion-free From Day 1 Through Week 24 of the OLEP100 (100.0 to 100.0)
SecondaryOLEP: Percentage of Participants Who Were Transfusion-free From Day 1 Through Week 52 of the OLEP
Time frame:
Day 1 through Week 52 of the OLEP
Reported as:
Number · percentage of participants
OLEP: Percentage of Participants Who Were Transfusion-free From Day 1 Through Week 52 of the OLEP
percentage of participantsParticipants With PNH
OLEP: Percentage of Participants Who Were Transfusion-free From Day 1 Through Week 52 of the OLEP80.0 (44.9 to 100.0)
SecondaryOLEP: Rate of RBC Transfusions From Day 1 Through Week 24 of the OLEP

The rate of units of transfusion for a participants was calculated based on the duration of treatment exposure of the participant.

Time frame:
Day 1 through Week 24 of the OLEP
Reported as:
Number · transfusions per person-year
OLEP: Rate of RBC Transfusions From Day 1 Through Week 24 of the OLEP
transfusions per person-yearParticipants With PNH
OLEP: Rate of RBC Transfusions From Day 1 Through Week 24 of the OLEP0 (NA to NA)
SecondaryOLEP: Rate of RBC Transfusions From Day 1 Through Week 52 of the OLEP

The rate of units of transfusion for a participants was calculated based on the duration of treatment exposure of the participant.

Time frame:
Day 1 through Week 52 of the OLEP
Reported as:
Number · transfusions per person-year
OLEP: Rate of RBC Transfusions From Day 1 Through Week 52 of the OLEP
transfusions per person-yearParticipants With PNH
OLEP: Rate of RBC Transfusions From Day 1 Through Week 52 of the OLEP0.200 (0.028 to 1.421)
SecondaryOLEP: Number of RBC Units Transfused From Day 1 Through Week 24 of the OLEP
Time frame:
Day 1 through Week 24 of the OLEP
Reported as:
Mean · RBC units
OLEP: Number of RBC Units Transfused From Day 1 Through Week 24 of the OLEP
RBC unitsParticipants With PNH
OLEP: Number of RBC Units Transfused From Day 1 Through Week 24 of the OLEP0 ± 0.0
SecondaryOLEP: Number of RBC Units Transfused From Day 1 Through Week 52 of the OLEP
Time frame:
Day 1 through Week 52 of the OLEP
Reported as:
Mean · RBC units
OLEP: Number of RBC Units Transfused From Day 1 Through Week 52 of the OLEP
RBC unitsParticipants With PNH
OLEP: Number of RBC Units Transfused From Day 1 Through Week 52 of the OLEP0.4 ± 0.9
SecondaryOLEP: Percentage of Participants With Breakthrough Hemolysis From Day 1 Through Week 24 of the OLEP

Breakthrough hemolysis was defined as having an LDH ≥ 2 x ULN and having signs or symptoms.

Time frame:
Day 1 through Week 24 of the OLEP
Reported as:
Number · percentage of participants
OLEP: Percentage of Participants With Breakthrough Hemolysis From Day 1 Through Week 24 of the OLEP
percentage of participantsParticipants With PNH
OLEP: Percentage of Participants With Breakthrough Hemolysis From Day 1 Through Week 24 of the OLEP0.0 (0.0 to 0.0)
SecondaryOLEP: Percentage of Participants With Breakthrough Hemolysis From Day 1 Through Week 52 of the OLEP

Breakthrough hemolysis was defined as having an LDH ≥ 2 x ULN and having signs or symptoms.

Time frame:
Day 1 through Week 52 of the OLEP
Reported as:
Number · percentage of participants
OLEP: Percentage of Participants With Breakthrough Hemolysis From Day 1 Through Week 52 of the OLEP
percentage of participantsParticipants With PNH
OLEP: Percentage of Participants With Breakthrough Hemolysis From Day 1 Through Week 52 of the OLEP0.0 (0.0 to 0.0)
SecondaryOLEP: Percentage of Participants Who Maintained Adequate Control of Hemolysis From Day 1 Through Week 24 of the OLEP

Adequate control was defined as LDH ≤ 1.5 x ULN.

Time frame:
Day 1 through Week 24 of the OLEP
Reported as:
Number · percentage of participants
OLEP: Percentage of Participants Who Maintained Adequate Control of Hemolysis From Day 1 Through Week 24 of the OLEP
percentage of participantsParticipants With PNH
OLEP: Percentage of Participants Who Maintained Adequate Control of Hemolysis From Day 1 Through Week 24 of the OLEP100 (100.0 to 100.0)
SecondaryOLEP: Percentage of Participants Who Maintained Adequate Control of Hemolysis From Day 1 Through Week 52 of the OLEP

Adequate control was defined as LDH ≤ 1.5 x ULN.

Time frame:
Day 1 through Week 52 of the OLEP
Reported as:
Number · percentage of participants
OLEP: Percentage of Participants Who Maintained Adequate Control of Hemolysis From Day 1 Through Week 52 of the OLEP
percentage of participantsParticipants With PNH
OLEP: Percentage of Participants Who Maintained Adequate Control of Hemolysis From Day 1 Through Week 52 of the OLEP100 (100.0 to 100.0)
SecondaryOLEP: Number of Participants Who Maintained Adequate Control of Hemolysis at Each Visit in OLEP

Adequate control was defined as LDH ≤ 1.5 x ULN at that visit.

Time frame:
Baseline, Days 57, 113, 169, 225, 281, 365 of the OLEP
Reported as:
Count of participants · Participants
OLEP: Number of Participants Who Maintained Adequate Control of Hemolysis at Each Visit in OLEP
ParticipantsParticipants With PNH
Baseline OLEP5
Day 57 OLEP5
Day 113 OLEP5
Day 169 OLEP5
Day 225 OLEP5
Day 281 OLEP5
Day 365 OLEP5
SecondaryOLEP: Number of Participants With Normalization of Their LDH at Each Visit in OLEP

Normalization was defined as LDH ≤ 1.0 x ULN at that visit.

Time frame:
Baseline, Days 57, 113, 169, 225, 281, 365 of the OLEP
Reported as:
Count of participants · Participants
OLEP: Number of Participants With Normalization of Their LDH at Each Visit in OLEP
ParticipantsParticipants With PNH
Baseline OLEP5
Day 57 OLEP5
Day 113 OLEP5
Day 169 OLEP5
Day 225 OLEP5
Day 281 OLEP5
Day 365 OLEP4
SecondaryOLEP: Average LDH From Day 1 Through Week 24 of the OLEP

The trapezoidal rule was used to calculate AUC. Individual mean LDH is defined as AUC divided by (last assessment date of LDH - first assessment date of LDH) of specific period.

Time frame:
Day 1 through Week 24 of the OLEP
Reported as:
Mean · U/L
OLEP: Average LDH From Day 1 Through Week 24 of the OLEP
U/LParticipants With PNH
OLEP: Average LDH From Day 1 Through Week 24 of the OLEP210.55 ± 42.64
SecondaryOLEP: Average LDH From Day 1 Through Week 52 of the OLEP

The trapezoidal rule was used to calculate AUC. Individual mean LDH is defined as AUC divided by (last assessment date of LDH - first assessment date of LDH) of specific period.

Time frame:
Day 1 through Week 52 of the OLEP
Reported as:
Mean · U/L
OLEP: Average LDH From Day 1 Through Week 52 of the OLEP
U/LParticipants With PNH
OLEP: Average LDH From Day 1 Through Week 52 of the OLEP210.13 ± 44.91
SecondaryOLEP: Percentage of Participants With Hemoglobin Stabilization From Day 1 Through Week 24 of the OLEP

Hemoglobin stabilization was defined as not receiving an RBC transfusion and having no decrease in hemoglobin level of ≥ 2 g/dL.

Time frame:
Day 1 through Week 24 of the OLEP
Reported as:
Number · percentage of participants
OLEP: Percentage of Participants With Hemoglobin Stabilization From Day 1 Through Week 24 of the OLEP
percentage of participantsParticipants With PNH
OLEP: Percentage of Participants With Hemoglobin Stabilization From Day 1 Through Week 24 of the OLEP100 (100.0 to 100.0)
SecondaryOLEP: Percentage of Participants With Hemoglobin Stabilization From Day 1 Through Week 52 of the OLEP

Hemoglobin stabilization was defined as not receiving an RBC transfusion and having no decrease in hemoglobin level of ≥ 2 g/dL.

Time frame:
Day 1 through Week 52 of the OLEP
Reported as:
Number · percentage of participants
OLEP: Percentage of Participants With Hemoglobin Stabilization From Day 1 Through Week 52 of the OLEP
percentage of participantsParticipants With PNH
OLEP: Percentage of Participants With Hemoglobin Stabilization From Day 1 Through Week 52 of the OLEP80.0 (44.9 to 100.0)
SecondaryOLEP: Change From Baseline in Hemoglobin Levels
Time frame:
Day 1 and Week 24 of the OLEP
Reported as:
Mean · g/dL
OLEP: Change From Baseline in Hemoglobin Levels
g/dLParticipants With PNH
OLEP: Change From Baseline in Hemoglobin Levels-0.10 ± 0.52
SecondaryOLEP: Change From Baseline in Hemoglobin Levels
Time frame:
Day 1 and Week 52 of the OLEP
Reported as:
Mean · g/dL
OLEP: Change From Baseline in Hemoglobin Levels
g/dLParticipants With PNH
OLEP: Change From Baseline in Hemoglobin Levels0.16 ± 0.70
SecondaryOLEP: Change From Baseline in FACIT-Fatigue Score

The FACIT-Fatigue is a 13-item, self-reported measure assessing an individual's level of fatigue during their usual daily activities over the past week. This questionnaire is part of the FACIT measurement system, a compilation of questions measuring health-related quality of life (QoL) in patients with cancer and other chronic illnesses. The FACIT-fatigue assesses the level of fatigue using a Likert scale ranging from 0 (not at all) to 4 (very much). Total scores range from 0 to 52, with higher scores indicating a higher quality of life.

Time frame:
Day 1 and Week 52 of the OLEP
Reported as:
Mean · score on a scale
OLEP: Change From Baseline in FACIT-Fatigue Score
score on a scaleParticipants With PNH
OLEP: Change From Baseline in FACIT-Fatigue Score-2.4 ± 8.7
SecondaryOLEP: Change From Baseline in HRQoL as Measured by the Global Health Status Subscale of the EORTC-QLQ-30 Scale

EORTC-QLQ-C30 is a 30-item self-reported questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. GHS subscale scores ranged from 0 to 100 with higher scores indicating better quality of life.

Time frame:
Day 1 and Week 52 of the OLEP
Reported as:
Mean · score on a scale
OLEP: Change From Baseline in HRQoL as Measured by the Global Health Status Subscale of the EORTC-QLQ-30 Scale
score on a scaleParticipants With PNH
OLEP: Change From Baseline in HRQoL as Measured by the Global Health Status Subscale of the EORTC-QLQ-30 Scale-10.000 ± 18.066
SecondaryOLEP: Change From Baseline in PF Scores on the EORTC QLQ-C30

EORTC-QLQ-C30 is a 30-item participant self-report questionnaire composed of both multi-item and single scales, including a PF scale. PF subscale scores ranged from 0 to 100 with higher scores indicating better quality of life.

Time frame:
Day 1 and Week 52 of the OLEP
Reported as:
Mean · score on a scale
OLEP: Change From Baseline in PF Scores on the EORTC QLQ-C30
score on a scaleParticipants With PNH
OLEP: Change From Baseline in PF Scores on the EORTC QLQ-C300.000 ± 4.714
SecondaryOLEP: Change From Baseline in CH50

This assay assessed the activity of the classical pathway of complement to measure C5 activity.

Time frame:
Baseline, Week 16, Week 32, Week 52 of the OLEP
Reported as:
Mean · IU/mL
OLEP: Change From Baseline in CH50
IU/mLParticipants With PNH
Change at Week 160.0 ± 0.0
Change at Week 320.6 ± 1.3
Change at Week 521.2 ± 1.8
SecondaryOLEP: Number of Participants With Pozelimab ADA
Time frame:
Day 1 through Week 52 of the OLEP
Reported as:
Count of participants · Participants
OLEP: Number of Participants With Pozelimab ADA
ParticipantsParticipants With PNH
OLEP: Number of Participants With Pozelimab ADA0
SecondaryOLEP: Number of Participants With Cemdisiran ADA
Time frame:
Day 1 through Week 52 of the OLEP
Reported as:
Count of participants · Participants
OLEP: Number of Participants With Cemdisiran ADA
ParticipantsParticipants With PNH
OLEP: Number of Participants With Cemdisiran ADA0

Adverse events

Collected over From signing informed consent up to 84 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OLTP: Participants With PNH0/6 (0%)1/6 (16.7%)6/6 (100%)
OLEP: Participants With PNH0/5 (0%)1/5 (20%)5/5 (100%)
Most frequent serious events
Most frequent serious events
EventOLTP: Participants With PNHOLEP: Participants With PNH
HaemolysisBlood and lymphatic system disorders0/61/5
Respiratory tract infectionInfections and infestations0/61/5
Endometrial hyperplasiaReproductive system and breast disorders1/60/5
Most frequent other events
Showing 10 of 29
Most frequent other events
EventOLTP: Participants With PNHOLEP: Participants With PNH
Injection site reactionGeneral disorders5/63/5
HeadacheNervous system disorders3/61/5
COVID-19Infections and infestations2/62/5
NasopharyngitisInfections and infestations1/62/5
HypertensionVascular disorders0/62/5
CoughRespiratory, thoracic and mediastinal disorders2/60/5
Viral upper respiratory tract infectionInfections and infestations1/61/5
Lower respiratory tract infectionInfections and infestations0/61/5
Respiratory tract infectionInfections and infestations0/61/5
SinusitisInfections and infestations0/61/5

Baseline characteristics

The safety analysis set included all participants who received any amount of study drug.

Age, Continuous
Age, Continuous(years)Participants With PNH
Mean51.3 ± 11.7
Sex: Female, Male
Sex: Female, Male(Participants)Participants With PNH
Female3
Male3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Participants With PNH
Hispanic or Latino0
Not Hispanic or Latino6
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Participants With PNH
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White6
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Regeneron Study Site
    Leeds, LS9 7TF, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in May 2022, 9 months.

Results were first posted in Jun 2025, 3 years 1 month after primary completion. A results delay was requested in May 2023.

Of 26 industry-sponsored phase 2 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 25. This study's 9 months is below that.

Counting every sponsor, half of 34 studies reached it within 24 months; a quarter within 12 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2021
First posted
May 17, 2021
StartActual
Jul 8, 2021
Primary completionActual
May 5, 2022
CompletionActual
May 4, 2023
Results delay requested
May 4, 2023
Results first posted
Jun 25, 2025
Last update
Aug 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04888507
Responsible party
Sponsor
First posted
May 17, 2021
Start date
Jul 8, 2021
Primary completion
May 5, 2022
Completion
May 4, 2023
Results posted
Jun 25, 2025
Last update
Aug 29, 2025

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pozelimab · Cemdisiran

Start the discussion